Glaxo Sues Spectrum Pharma Over Imitrex Patent Challenge

Law360, New York (February 19, 2005, 12:00 AM EST) -- GlaxoSmithKline has sued specialty drug maker Spectrum Pharmaceuticals, Inc. over its challenge to Glaxo’s patent for the migraine injection treatment Imitrex.

Glaxo filed its lawsuit on Friday to prevent Spectrum from proceeding with the commercialization of its product. This action formally initiates the patent challenge process under the Hatch-Waxman Act.

The venue of the lawsuit and the attorneys involved were not immediately available.

In October of last year, Spectrum submitted an Abbreviated New Application (ANDA) with the U.S. Food and Drug Administration containing a Paragraph IV...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.